NEWPORT NEWS, Va., Feb 7 /PRNewswire/ -- Dilon Technologies, makers of a gamma imaging system optimized for early breast cancer detection, has appointed Robert G. Moussa to the position of President and Chief Executive Officer.
Moussa has a long and successful record in the medical device industry having held a number of senior positions at both Sherwood Medical Industries and Mallinckrodt Medical -- a health care corporation he ran as CEO for a number of years. In his four years at Mallinckrodt, Moussa grew revenues from $350 million to $1.2 billion and increased the operating margins from 18 percent to 22 percent. Additionally, he has successfully launched a number of new products in the diagnostic, nuclear medicine and medical device markets.
Dilon "the standard of care"
Regarding Dilon Moussa commented, "Dilon has advanced technology that will make it a major weapon in the battle against cancer. Based upon existing clinical results, it will become the standard of care as an adjunct diagnostic tool in the diagnosis of breast cancer."
Under Moussa's leadership, Dilon will adopt a 4-point strategy to
increase market share.
The strategy includes:
1) Expansion of the established installed base in the US through strategic
use of sales and distribution.
2) Initiating a major international expansion strategy. This is based on
Dilon's international potential of being at least as large as that in
3) Working with the Medical Establishment, expand the capabilities and
indications for the existing BSGI product.
4) Pursue acquisitions of products, technologies and companies that offer
a strategic fit with Dilon.
Moussa added, "I am confident that by adopting and accelerating these measures, we will achieve the objective of making Dilon the standard of care in the diagnostic field."
About Dilon Technologies LLC<
|SOURCE Dilon Technologies LLC|
Copyright©2008 PR Newswire.
All rights reserved